CVE-2022-15213.2.4 IMPROPER ACCESS CONTROL CWE-284
Updated under an hour ago ()
Does this affect you?
It affects Illumina NextSeq 550Dx and 7 other products. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 1.14%, higher than 67% of scored CVEs.
Do this next
Free account, 1 product
LRM does not implement authentication or authorization by default. A malicious actor can inject, replay, modify, and/or intercept sensitive data.
- CVSS
- 9.1 CRITICAL (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
- Weakness (CWE)
- CWE-284
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 1.14% (percentile 67)
- Assigned by
- icscert
- NVD analysis
- Modified
- Record last updated
- Apr 16, 2025
- First seen by InfoSec Signals
- Oct 12, 2026
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.